On January 4, 2024, C4 Therapeutics, Inc. closed the transaction. The company issued 5,567,928 shares at an issue price of $4.49 per share for the gross proceeds of $24,999,996.72.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.16 USD | -9.41% | -8.61% | +9.03% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
42.84 CNY | -3.08% | +2.66% | 2.56B | ||
6.16 USD | -9.41% | -8.61% | 468M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.03% | 468M | |
+17.96% | 47.02B | |
+48.77% | 41.86B | |
+1.17% | 41.76B | |
-4.27% | 28.8B | |
+11.42% | 26.05B | |
-21.39% | 19.15B | |
+4.86% | 12.55B | |
+27.29% | 12.34B | |
-3.50% | 11.82B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.